J.P. Morgan Maintains Underweight on Edwards Lifesciences

J.P. Morgan is out with its report today on Edwards Lifesciences EW, maintaining Underweight. In a note to clients, J.P. Morgan writes, "We view TAVI as one of the most exciting opportunities in MedTech over the next decade, with WW sales projected to approach $2.3B by 2015. Edwards is uniquely positioned to lead the way in this market in our view. However, despite the attractiveness of the opportunity, we struggle to see value for investors at current levels." At the time of posting, shares of EW were trading pre-market at $83.86, up 1.59% from Thursday's close.